加载中
NASDAQHealthcareMedical - Pharmaceuticals
最新数据
US$0.8398
+US$0.0048 · +0.57%
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
前收盘价
US$0.8398
+US$0.0048 · +0.57%
盘中时间采用ET。市场数据可能有所延迟。
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
日内区间
当前US$0.8398
52周区间
当前US$0.8398
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
41
合理估值
情绪
44
多空交织
风险
97
极高风险
动量
19
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
日内区间
当前US$0.8398
52周区间
当前US$0.8398
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|
| 研究与开发 | 641.83万 USD | 492.5万 USD | 424.05万 USD | 685.57万 USD |
| 销售、一般及管理费用 | 1710.44万 USD | 1564.77万 USD | 788.08万 USD | 285.75万 USD |
| 营业费用 | 2352.28万 USD | 2057.27万 USD | 1212.12万 USD | 971.32万 USD |
| 利息收入 | 3.64万 USD | — | — | — |
| 利息支出 | 21.8万 USD | — | — | — |
| 折旧和摊销 | — | — | — | 971.32万 USD |
| 营业利润 | −2352.28万 USD | −2057.27万 USD | −1212.12万 USD | −971.32万 USD |
| 净利润 | −2476.14万 USD | −2114.87万 USD | −1269.72万 USD | −1086.52万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$6.00
上涨空间 614.46%报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
